We created a Personal Account for you to make the process of buying faster and easier in the future.To activate, use the link in the E-mail that we have sent to you
Erlotinib has shown a survival benefit in the treatment of lung
cancer in phase III trials. The SATURN (Sequential in Unresectable
NSCLC) study found that erlotinib added to chemotherapy improved
overall survival by 19%, and improved progression-free survival
(PFS) by 29%, when compared to chemotherapy alone.